z-bio 2025-10-31 2955

　　Professor Li Weimin from West China Hospital of Sichuan University is committed to clinical and translational research on key technologies for early diagnosis and treatment of lung cancer and lung infection, and has recently published many articles.　　

　　Article 1 the BMJ

　　Recently, Professor Li Weimin, together with Professor Huang Jin, Director of the Center for Integrated Medical-Industrial Innovation and Transformation, and Professor Chen Lei, Vice President of the Plateau Medical Research Institute and Deputy Director of the Institute of Neurological Diseases, published an analytical article titled "Breadth versus depth: balancing variables, sample size, and quality in Chinese cohort studies" in the top medical journal "Breadth versus depth: balancing variables, sample size, and quality in Chinese cohort studies".

　　For the first time, the study empirically reveals the structural imbalance between the breadth of variables, depth of sample size and research quality in China's current large-scale cohort expansion, and proposes value-driven systemic solutions. This article was included in the BMJ "Advancing China and International Cohort Research" album, and is also the only research article in the album whose authors are all clinicians.

　　Chapter 2 Nature Biomedical Engineering

　　Mucosal immunity can effectively prevent upper respiratory tract infections and limit virus shedding and spread. However, currently, the World Health Organization has not approved any nasal spray COVID-19 vaccine for global use.

　　Li Weimin, Wei Xiawei, Yang Li, Lu Guangwen, Wang Youchun, Sun Qiangming, and Lu Shuayao of the Chinese Academy of Medical Sciences jointly published a research paper titled "Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant" online.

　　This study developed a two-component intranasal vaccine that combines an adenoviral vector expressing the XBB.1.5 variant spike protein (Ad5XBB.1.5) with a self-assembling trimeric recombinant protein derived from the receptor binding domain (RBDXBB.15-HR).

　　Article 3 Nature Communications

　　Lung cancer is the world’s number one “cancer killer” and the malignant tumor with the highest morbidity and mortality rates in my country. Currently, the most effective treatment for stage I lung cancer is surgical resection, but the postoperative recurrence rate is about 20-40%. Once recurrence and metastasis occur, the 5-year survival rate of patients is only about 15%, but the biological mechanism behind this is still unclear.

　　Based on this, the team of Professor Li Weimin, researcher Wang Chengdi and researcher Zhang Li from the Institute of Respiratory Health jointly published a study titled "Multi-omics analyzes reveal biological and clinical insights in recurrent stage I non-small cell lung cancer".

　　The research team conducted a joint analysis of the genome, epigenome and transcriptome on a cohort of patients with stage I non-small cell lung cancer, systematically revealed the molecular characteristics of postoperative recurrence and metastasis in lung cancer patients, and proposed new molecular classification and targeted treatment strategies through multi-omics integration, providing new ideas for in-depth understanding of the molecular mechanisms of postoperative recurrence and metastasis of non-small cell lung cancer and clinical decision-making and intervention.

　　Chapter 4 The Innovation

　　Pulmonary infectious diseases caused by different pathogens have brought serious disease burdens to people's lives and health. Chest computed tomography (CT) is an important auxiliary tool for diagnosing pulmonary infections, but its phenomenon of "different diseases have the same symptoms and the same disease has different symptoms" makes accurate diagnosis difficult.

　　Based on this, the team of Professor Li Weimin and researcher Wang Chengdi jointly published a research paper titled "A multimodal integration pipeline for accurate diagnosis, pathogen identification, and prognosis prediction of pulmonary infections".　　

　　The study included 24,107 inpatients from West China Hospital of Sichuan University and the Medical Consortium, and collected their clinical symptoms, diagnosis and treatment records, laboratory test results, and chest CT images. The attention architecture was used to merge the single-modal features extracted by the model from clinical, imaging, and inspection data into multi-modal features, allowing the MMI model to integrate multiple information sources and effectively diagnose the disease accurately.

　　This study innovatively developed a multi-modal fusion MMI model to accurately diagnose pulmonary infectious diseases, quickly identify pathogens, and integrate multi-dimensional features to achieve early warning of severe illness, which is helpful for timely clinical decision-making and intervention, improves the prognosis of patients with pulmonary infectious diseases, and provides new ideas for accurate diagnosis and treatment of pulmonary infectious diseases.